A Phase 2 interventional study of Paliperidone palmitate in Schizophrenia, sponsored by Janssen Pharmaceutical K.K.. Completed at 1 site in Japan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-06-05.
Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 89th largest by enrollment, is one of 15 that started in 2007, is one of 5 in phase 2, and was the 78th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 20 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 15 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is below the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Pharmaceutical K.K., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 129th largest by enrollment of the 176 interventional ones that give a count, is one of 24 that started in 2007, is one of 11 in phase 2, and was the 165th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and safety of paliperidone palmitate in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).
This is a multicenter (when more than one hospital or medical school team work on a medical research study), open-label (all people know the identity of the intervention), randomized (the study drug is assigned by chance), parallel-group (Each group of participants will be treated at the same time), comparison study to assess the pharmacokinetics and safety of paliperidone palmitate (study medication) in participants with schizophrenia. The study comprises a 64-day Treatment period and a 155-day Follow-up period. The participants will be randomly assigned to one of the four study groups. The study medication will be administered on Days 1, 8, 36 and 64. Pharmacokinetics of the study medication will be assessed as primary outcome. Participants' safety will be monitored throughout the study.
Inclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paliperidone palmitate 50 milligram (mg) intramuscular (into the muscle) injection on Days 1, 8, 36 and 64.
Drug: Paliperidone palmitate
Paliperidone palmitate 100 mg intramuscular injection on Days 1, 8, 36 and 64.
Drug: Paliperidone palmitate
Paliperidone palmitate 150 mg intramuscular injection on Days 1, 8, 36 and 64.
Drug: Paliperidone palmitate
Paliperidone palmitate 150 mg intramuscular injection on Day 1 and paliperidone palmitate 50 mg intramuscular injection on Days 8, 36 and 64.
Drug: Paliperidone palmitate
Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
Also known as: JNS010
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 8
The pre-dose plasma concentration (Cpredose) at Day 8 is defined as the plasma concentration obtained before a dose is given on Day 8. The mean Cpredose at Day 8 was measured in nanogram per milliliter (ng/ml).
Time frame: Day 8
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 36
The Cpredose at Day 36 is defined as the plasma concentration obtained before a dose is given on Day 36. The mean Cpredose at Day 36 was measured in ng/ml.
Time frame: Day 36
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 64
The Cpredose at Day 64 is defined as the plasma paliperidone concentration obtained before a dose is given on Day 64. The mean Cpredose at Day 64 was measured in ng/ml.
Time frame: Day 64
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 92
The Cpredose at Day 92 is defined as the plasma paliperidone concentration obtained after the treatment interval of the study drug (that is 4 weeks) passed after the final dose (Day 92). The mean Cpredose at Day 92 was measured in ng/ml.
Time frame: Day 92
Maximum Observed Plasma Concentration (Cmax) of Paliperidone
The Cmax is defined as maximum observed analyte concentration.
Time frame: Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Paliperidone
The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
Time frame: Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)
The AUCtau is a measure of the plasma paliperidone concentration from time zero to end of dosing interval. It is used to characterize drug absorption.
Time frame: Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
Plasma Paliperidone Concentration at Steady State (Css av)
The Css av is defined as value of average analyte concentration at steady-state (after 4 Intramuscular Injections of Paliperidone Palmitate).
Time frame: Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
Paliperidone Plasma Decay Half-Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 8
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
Time frame: Day 8
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 22
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
Time frame: Day 22
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 50
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
Time frame: Day 50
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 78
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
Time frame: Day 78
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 92
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
Time frame: Day 92
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 120
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
Time frame: Day 120
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 162
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
Time frame: Day 162
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 218
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
Time frame: Day 218
Positive and Negative Syndrome Scale (PANSS) Total Score
The PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).
Time frame: Baseline, Day 8, 22, 50, 78 and 92
Number of Participants With Clinical Global Impression Severity (CGI-S) Score
The CGI-S rating scale is a 7 point (1-absent, 2-minimal, 3-mild, 4-moderate, 5-moderate severe, 6-severe, 7-extreme) global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "normal, not at all ill" and a rating of 7 is equivalent to "among the most extremely ill participants". Higher scores indicate worsening.
Time frame: Baseline, Day 8, 22, 50, 78 and 92
| Milestone | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| Started | 14 | 14 | 14 | 14 |
| Completed | 12 | 10 | 14 | 11 |
| Not completed | 2 | 4 | 0 | 3 |
| Withdrew: Withdrawal by subject | 1 | 3 | 0 | 2 |
| Withdrew: Adverse event | 1 | 1 | 0 | 1 |
The pre-dose plasma concentration (Cpredose) at Day 8 is defined as the plasma concentration obtained before a dose is given on Day 8. The mean Cpredose at Day 8 was measured in nanogram per milliliter (ng/ml).
| ng/ml | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 8 | 5.85 ± 4.47 | 7.28 ± 4.92 | 28.4 ± 29.2 | 12.1 ± 7.46 |
The Cpredose at Day 36 is defined as the plasma concentration obtained before a dose is given on Day 36. The mean Cpredose at Day 36 was measured in ng/ml.
| ng/ml | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 36 | 6.77 ± 3.75 | 14.5 ± 5.76 | 23.4 ± 18.6 | 19.5 ± 16.1 |
The Cpredose at Day 64 is defined as the plasma paliperidone concentration obtained before a dose is given on Day 64. The mean Cpredose at Day 64 was measured in ng/ml.
| ng/ml | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 64 | 6.86 ± 3.31 | 15.1 ± 9.16 | 22.9 ± 16.3 | 14.3 ± 9.01 |
The Cpredose at Day 92 is defined as the plasma paliperidone concentration obtained after the treatment interval of the study drug (that is 4 weeks) passed after the final dose (Day 92). The mean Cpredose at Day 92 was measured in ng/ml.
| ng/ml | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 92 | 8.41 ± 4.51 | 15.2 ± 6.21 | 25.4 ± 16.8 | 13.5 ± 6.38 |
The Cmax is defined as maximum observed analyte concentration.
| ng/ml | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Paliperidone | 13.7 ± 7.52 | 33.5 ± 19.8 | 43.1 ± 30.3 | 21.6 ± 12.9 |
The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
| Days | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Paliperidone | 10.99 (1.99 to 21.01) | 7.89 (5.97 to 21.81) | 7.50 (2.93 to 27.01) | 3.82 (0.71 to 7.07) |
The AUCtau is a measure of the plasma paliperidone concentration from time zero to end of dosing interval. It is used to characterize drug absorption.
| nanogram*hour per milliliter | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) | 7081 ± 3581 | 15898 ± 7535 | 21853 ± 15534 | 11109 ± 5390 |
The Css av is defined as value of average analyte concentration at steady-state (after 4 Intramuscular Injections of Paliperidone Palmitate).
| ng/ml | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| Plasma Paliperidone Concentration at Steady State (Css av) | 10.7 ± 5.42 | 23.9 ± 11.4 | 32.8 ± 23.1 | 16.7 ± 8.28 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| Days | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| Paliperidone Plasma Decay Half-Life (t1/2) | 68.1 ± 48.0 | 58.5 ± 29.1 | 95.5 ± 98.8 | 104.4 ± 97.1 |
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
| Participants | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| None | 6 | 9 | 6 | 6 |
| Very mild | 8 | 5 | 6 | 7 |
| Mild | 0 | 0 | 2 | 1 |
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
| Participants | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| None | 7 | 7 | 6 | 6 |
| Very mild | 7 | 6 | 7 | 8 |
| Mild | 0 | 0 | 1 | 0 |
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
| Participants | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| None | 11 | 7 | 8 | 6 |
| Very mild | 3 | 5 | 5 | 6 |
| Mild | 0 | 0 | 1 | 0 |
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
| Participants | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| None | 9 | 8 | 8 | 6 |
| Very mild | 4 | 4 | 5 | 5 |
| Mild | 0 | 0 | 1 | 0 |
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
| Participants | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| None | 7 | 7 | 7 | 5 |
| Very mild | 6 | 5 | 6 | 6 |
| Mild | 0 | 0 | 1 | 0 |
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
| Participants | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| None | 9 | 6 | 6 | 6 |
| Very mild | 4 | 5 | 6 | 5 |
| Mild | 0 | 0 | 2 | 0 |
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
| Participants | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| None | 9 | 7 | 6 | 7 |
| Very mild | 3 | 4 | 6 | 4 |
| Mild | 0 | 0 | 2 | 0 |
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe). Overall severity was assessed at 5 levels (0 \[none, normal\]; 1 \[Very Mild\]; 2 \[Mild\]; 3 \[Moderate\]; 4 \[severe\]).
| Participants | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| None | 9 | 7 | 6 | 6 |
| Very mild | 3 | 4 | 7 | 5 |
| Mild | 0 | 0 | 1 | 0 |
The PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).
| units on a scale | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| Baseline (n = 14, 14, 14, 14) | 61.9 ± 12.39 | 60.7 ± 17.28 | 60.4 ± 16.76 | 63.9 ± 15.58 |
| Day 8 (n = 14, 14, 13, 14) | 60.0 ± 13.85 | 59.6 ± 19.44 | 57.8 ± 17.21 | 62.6 ± 15.33 |
| Day 22 (n = 14, 14, 14, 14) | 56.8 ± 13.19 | 58.1 ± 19.59 | 57.1 ± 16.10 | 60.4 ± 13.15 |
| Day 50 (n = 14, 14, 14, 14) | 57.9 ± 17.49 | 60.0 ± 20.47 | 56.5 ± 15.04 | 62.8 ± 13.89 |
| Day 78 (n = 14, 14, 14, 14) | 56.4 ± 17.07 | 60.4 ± 20.05 | 57.2 ± 18.55 | 59.9 ± 13.03 |
| Day 92 (n = 14, 14, 14, 14) | 56.4 ± 17.79 | 60.2 ± 20.38 | 57.4 ± 17.83 | 60.6 ± 13.52 |
The CGI-S rating scale is a 7 point (1-absent, 2-minimal, 3-mild, 4-moderate, 5-moderate severe, 6-severe, 7-extreme) global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "normal, not at all ill" and a rating of 7 is equivalent to "among the most extremely ill participants". Higher scores indicate worsening.
| Participants | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| Baseline, Minimal (n=14,14,14,14) | 3 | 4 | 3 | 1 |
| Baseline, Mild (n=14,14,14,14) | 8 | 6 | 10 | 8 |
| Baseline, Moderate (n=14,14,14,14) | 3 | 3 | 1 | 5 |
| Baseline, Moderate severe (n=14,14,14,14) | 0 | 1 | 0 | 0 |
| Day 8, Minimal (n=14,14,13,14) | 3 | 3 | 3 | 1 |
| Day 8, Mild (n=14,14,13,14) | 8 | 7 | 9 | 10 |
| Day 8, Moderate (n=14,14,13,14) | 3 | 2 | 1 | 3 |
| Day 8, Moderate severe (n=14,14,13,14) | 0 | 2 | 0 | 0 |
| Day 22, Minimal (n=14,14,14,14) | 4 | 5 | 4 | 2 |
| Day 22, Mild (n=14,14,14,14) | 8 | 5 | 9 | 9 |
| Day 22, Moderate (n=14,14,14,14) | 2 | 3 | 1 | 3 |
| Day 22, Moderate severe (n=14,14,14,14) | 0 | 1 | 0 | 0 |
| Day 50, Minimal (n=14,14,14,14) | 5 | 5 | 3 | 0 |
| Day 50, Mild (n=14,14,14,14) | 7 | 4 | 10 | 13 |
| Day 50, Moderate (n=14,14,14,14) | 1 | 3 | 1 | 0 |
| Day 50, Moderate severe (n=14,14,14,14) | 1 | 2 | 0 | 1 |
| Day 78, Minimal (n=14,14,14,14) | 6 | 5 | 5 | 1 |
| Day 78, Mild (n=14,14,14,14) | 6 | 4 | 8 | 12 |
| Day 78, Moderate (n=14,14,14,14) | 1 | 3 | 0 | 1 |
| Day 78, Moderate severe (n=14,14,14,14) | 1 | 2 | 1 | 0 |
| Day 92, Minimal (n=14,14,14,14) | 5 | 4 | 5 | 1 |
| Day 92, Mild(n=14,14,14,14) | 7 | 5 | 8 | 11 |
| Day 92, Moderate (n=14,14,14,14) | 1 | 3 | 0 | 2 |
| Day 92, Moderate severe (n=14,14,14,14) | 1 | 2 | 1 | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paliperidone Palmitate 50 mg | — | 1/14 (7.1%) | 14/14 (100%) |
| Paliperidone Palmitate 100 mg | — | 0/14 (0%) | 14/14 (100%) |
| Paliperidone Palmitate 150 mg | — | 2/14 (14.3%) | 14/14 (100%) |
| Paliperidone Palmitate 150/ 50 mg | — | 3/14 (21.4%) | 14/14 (100%) |
| Event | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| Psychiatric symptomPsychiatric disorders | 0/14 | 0/14 | 0/14 | 2/14 |
| SchizophreniaPsychiatric disorders | 1/14 | 0/14 | 0/14 | 0/14 |
| Suicide attemptPsychiatric disorders | 0/14 | 0/14 | 1/14 | 0/14 |
| ConvulsionNervous system disorders | 0/14 | 0/14 | 0/14 | 1/14 |
| Grand mal convulsionNervous system disorders | 0/14 | 0/14 | 1/14 | 0/14 |
| Neuroleptic malignant syndromeNervous system disorders | 0/14 | 0/14 | 1/14 | 0/14 |
| HypothermiaGeneral disorders | 0/14 | 0/14 | 1/14 | 0/14 |
| Event | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg |
|---|---|---|---|---|
| Blood prolactin increasedInvestigations | 11/14 | 9/14 | 13/14 | 10/14 |
| Psychiatric symptomPsychiatric disorders | 5/14 | 6/14 | 3/14 | 3/14 |
| NasopharyngitisInfections and infestations | 5/14 | 4/14 | 4/14 | 4/14 |
| InsomniaPsychiatric disorders | 3/14 | 3/14 | 4/14 | 1/14 |
| Weight increasedInvestigations | 4/14 | 2/14 | 3/14 | 2/14 |
| HypertensionVascular disorders | 3/14 | 0/14 | 0/14 | 0/14 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 1/14 | 1/14 | 2/14 | 3/14 |
| Back painMusculoskeletal and connective tissue disorders | 1/14 | 0/14 | 1/14 | 3/14 |
| Injection site painGeneral disorders | 1/14 | 1/14 | 3/14 | 2/14 |
| Weight decreasedInvestigations | 3/14 | 3/14 | 1/14 | 2/14 |
| Age Continuous(Years) | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg | Total |
|---|---|---|---|---|---|
| Mean | 46.4 ± 13.8 | 45.2 ± 11.1 | 48.7 ± 11.8 | 49.4 ± 12.1 | 47.4 ± 12.0 |
| Sex: Female, Male(Participants) | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg | Total |
|---|---|---|---|---|---|
| Female | 2 | 5 | 3 | 6 | 16 |
| Male | 12 | 9 | 11 | 8 | 40 |
| Number of Participants with Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score(Participant) | Paliperidone Palmitate 50 mg | Paliperidone Palmitate 100 mg | Paliperidone Palmitate 150 mg | Paliperidone Palmitate 150/ 50 mg | Total |
|---|---|---|---|---|---|
| None | 8 | 8 | 5 | 5 | 26 |
| Very mild | 6 | 6 | 8 | 9 | 29 |
| Mild | 0 | 0 | 1 | 0 | 1 |
The record gives a start of Jan 2007, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 5 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone